Safety and tolerability of spesolimab in patients with ulcerative colitis
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2022.2103536
Abstract: ABSTRACT Background Interleukin (IL)-36 signaling has been shown to be increased in ulcerative colitis (UC). Spesolimab, a novel humanized monoclonal antibody, targets the IL-36 pathway. Research Design and Methods We report safety, immunogenicity, and efficacy… read more here.
Keywords: safety; spesolimab; placebo; ulcerative colitis ... See more keywords
Rapid and sustained response to Spesolimab in five Chinese patients with generalized pustular psoriasis.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and experimental dermatology"
DOI: 10.1093/ced/llad108
Abstract: Generalized pustular psoriasis (GPP) is a rare skin disease characterized by generalized sterile pustules with or without severe systemic symptoms. Here we share our experience with Spesolimab in 5 Chinese GPP flare patients. read more here.
Keywords: spesolimab; sustained response; generalized pustular; pustular psoriasis ... See more keywords
Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare
Sign Up to like & getrecommendations! Published in 2021 at "BMJ Open"
DOI: 10.1136/bmjopen-2020-043666
Abstract: Introduction Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening disease characterised by recurrent flares of widespread neutrophilic aseptic skin pustular eruption. Despite the availability of approved biologics for GPP in Japan, Taiwan and Thailand,… read more here.
Keywords: spesolimab; presenting acute; study; generalized pustular ... See more keywords